ADC & Bioconjugate East Asia brings top experts together to advance ADC innovation and collaboration across biopharma, CMOs/CROs, regulators, and academia.
Debuting in 2025, ADC & Bioconjugate East Asia (ADCBio) will bring together leading experts and innovators from South Korea, Japan, China, and Taiwan to explore the latest breakthroughs in ADCs and bioconjugation. As East Asia accelerates advancements in targeted therapies, ADCBio will serve as a pivotal platform for fostering collaboration among Asia’s leading ADC biopharma and big pharma, CMOs/CROs, regulatory authorities, and academic research institutes.
The conference will delve into cutting-edge ADC development and bioconjugation strategies, focusing on enhancing efficacy, scalability, and manufacturability. Key discussions will cover preclinical and discovery advancements, process optimization, CMC considerations, and market access strategies. With an emphasis on bridging scientific innovation with clinical and commercial success, ADCBio will provide critical insights into the evolving ADC landscape.
Under the umbrella of Biologics World Korea 2025, ADCBio will be co-located with Biologics Manufacturing Korea 2025 and CGT East Asia 2025 offering a unique cross-disciplinary platform for networking, knowledge-sharing, and business growth. Whether you seek regulatory insights, investment opportunities, or strategic partnerships, ADCBio is the premier event to connect with East Asia’s key players in the ADC ecosystem.
